June 25, 2020
Dear CDKL5 Deficiency Disorder and Dup15q Syndrome Communities,
Last week we shared with IFCR and Dup15q Alliance news that enrollment for the ARCADE study is complete.
The Ovid team wishes to extend our sincere thanks to the community for constant and unwavering support in working together to achieve this milestone. It is truly an honor for our team to continue a meaningful relationship with the community as we work to accelerate the potential development of soticlestat for patients affected by rare epilepsies.
Our shared goal is to bring potential treatments to patients with high unmet need and few or no approved treatment options. By completing enrollment now, we take another step forward in this process. It is because of the CDD and Dup15q community’s work in driving awareness of the ARCADE study that we are able to make this decision and complete enrollment. This community continues to have great impact on Ovid’s development process, thank you.
Working closely with study investigators and advocacy organizations we are confident that we can evaluate outcomes from ARCADE in late summer or early fall of this year. This gives us a clear path forward once data from the trial is analyzed. At that time, we will update the community about development plans for soticlestat in patients with CDKL5 Deficiency Disorder and Dup15q Syndrome. As always, we want to ensure open and transparent communication with the community, so please know we will continue to update you regularly.
Again, it is with sincere thanks to the entire community that we share this news. From the Ovid family to each of yours, we wish you all the best.
Sincerely,
Sophia Cacciatore Manager,
Patient Advocacy
